Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning

This study looks at patients admitted to intensive care for drug poisoning involving metformin, a common diabetes medication. Researchers will compare two groups: patients who overdosed on metformin alone and those who took both metformin and dapagliflozin, another diabetes drug. The goal is to find clinical or laboratory signs that could help doctors quickly recognize a dapagliflozin overdose in this context, which could improve treatment and patient outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Drug Overdose Acid-Base Imbalance Acidosis Acidosis, Lactic Chemically-Induced Disorders Dapagliflozin Diabetes Complications Diabetes Mellitus Diabetic Ketoacidosis Drug Misuse Endocrine System Diseases Intensive Care Units Ketosis Lactic Acidosis Mental Disorders Metabolic Diseases Metformin Nutritional and Metabolic Diseases Prescription Drug Misuse Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier de Saint-Denis

Saint-Denis, France

Location status: Recruiting

Location contact

Nolan HASSOLD

CONTACT

[email protected]

0142356140

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 18 years or older
Admission to an intensive care unit (ICU) due to acute drug poisoning
Documented exposure to either:
Metformin alone
Metformin in combination with dapagliflozin

Exclusion criteria

Patients under 18 years of age
No exposure to metformin
Exposure to dapagliflozin without metformin

Treatment and study plan

Primary outcomes

Identification of clinical and biological differences between patients admitted to intensive care for metformin overdose alone versus those with combined metformin and dapagliflozin overdose.

Time frame: 10 years

Sponsors and collaborators

Lead sponsor

Centre Hospitalier de Saint-Denis

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Sep 25, 2025
Registry last updated: Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting